TriangleBiospecimen Collection (NCT07748611)
Biospecimen Collection trial for Borderline Resectable Pancreatic Ductal Adenocarcinoma (NCT07748611). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated, removable or borderline-removable pancreatic ductal adenocarcinoma. It excludes mismatch-repair deficiency, Lynch syndrome, MSI-high disease and homologous recombination deficiency.
The idea: use SMAD4 testing to choose chemotherapy before surgery. SMAD4-mutant cancers get gemcitabine plus nab-paclitaxel, which disrupt DNA production and cell division. For SMAD4-wild-type cancers, doctors choose that pair or FOLFIRINOX, a four-drug chemotherapy regimen. Radiation is optional.
This phase 2 study plans 125 patients. Brett Ecker leads at Northwestern University in Chicago, the only recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.